Coherus reports Q2 2026 results, flags October data update for tagmokitug
Coherus said LOQTORZI revenue rose 15% sequentially as it pointed to October for more mature clinical data on its CCR8 antibody in head and neck cancer.
Coherus Oncology reported second quarter 2026 results on August 5, 2026, and said it expects to publicly disclose data sets with sufficient maturity in October 2026, according to the release.
Chief Medical Officer Rosh Dias said the company completed enrollment of casdozokitug in HCC and of tagmokitug in HNSCC and CRC, with emerging evidence of clinical activity in combination with toripalimab in HNSCC, reinforcing confidence in the Treg depletion mechanism.1
On the pipeline timeline, Coherus said Phase 1b dose-optimization studies of tagmokitug combined with toripalimab in second-line HNSCC and upper gastrointestinal adenocarcinomas remain ongoing, with initial data readouts expected in the second half of 2026.1 The company also said a Phase 1b study of tagmokitug plus toripalimab, with and without chemotherapy, in first- and second-line esophageal squamous cell carcinoma continues to enroll, with initial data expected in the second half of 2026.1 Separately, the Phase 1b/2a study of tagmokitug and toripalimab in fourth-line-and-beyond colorectal cancer without liver metastasis is fully enrolled, with initial data expected in the second half of 2026.1 Coherus said a Phase 1b study combining tagmokitug with the bispecific antibody pasritamig in metastatic castration-resistant prostate cancer is expected to begin in fall 2026.1
For casdozokitug, the company said enrollment is complete in the randomized Phase 2 trial of casdozokitug, toripalimab and bevacizumab in first-line unresectable hepatocellular carcinoma, with the first data readout expected in the second half of 2026.1
On commercial performance, Coherus said LOQTORZI revenue for the second quarter was $13.6 million, up 37% from $10.0 million a year earlier and up 15% from $11.8 million in the first quarter, which the company said had been affected by severe weather and seasonality.1
On finances, the company reported cash, cash equivalents and marketable securities of $105.3 million as of June 30, 2026, down from $172.1 million at the end of 2025.1 It noted part of that balance reflects Transition Service Agreement-related collections tied to payables and accrued liabilities totaling $22.7 million at midyear, versus $65.1 million at year-end 2025.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.